Exclusive Summary

• UB390 is a First-in-class ROR1-targeting ADC utilizing an Eribulin payload, demonstrating immense Best-in-class potential for both pan-solid tumors and hematological malignancies.
• Leveraging a unique payload and cleavable linker, it is engineered to overcome acquired resistance to prevalent Topo I inhibitors (e.g., DXd) and delivers robust efficacy in tumors with medium or low ROR1 expression.
• Preclinical head-to-head benchmarking proves that UB390 significantly outperforms the phase-leading competitor MK-2140 in target binding affinity, cellular internalization, and cytotoxicity.
• With completely unencumbered ex-China rights and a comprehensive global patent layout extendable up to 2049, UB390 represents a highly strategic and lucrative License-out target for global pharmaceutical companies.

Asset Materials

Contact Us for Full Materials